Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON44455
NL-OMON44455
Recruiting
Not Applicable

PRISMA study: Personalised RISk-based MAmmascreening - PRISMA study

Health Evidence0 sites90,000 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbreast cancermamma carcinoma10006291

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
breast cancer
Sponsor
Health Evidence
Enrollment
90000
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Health Evidence

Eligibility Criteria

Inclusion Criteria

  • •\- Women invited for breast cancer screening
  • •\- Able to communicate in Dutch
  • •\- Able to read and understand the participant information and informed consent form

Exclusion Criteria

  • •\- Women who cannot make the decision to participate by themselves (mentally ill or mentally handicapped)
  • •\- Not able to fill out a web\-based questionnaire

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Healthy Pregnancy 4 All -2: Maternity carePregnancy, patient tailored care, maternity care, antenatal care, maternal empowerment
NL-OMON29568The research team has received funding from the Ministry of Health, Welfare and Sports in order to execute the Healthy Pregnancy 4 All study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of a manuscript.1,711
Completed
Not Applicable
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)Breast Cancer
NCT02269813West German Study Group452
Active, not recruiting
Phase 1
Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that are postpubertal and/or adult consisting of lowering RT,chemotherapy doses and adding an investigative drug.
EUCTR2020-003063-26-FREuropean Organisation for Research and Treatment of205
Not yet recruiting
Not Applicable
Presepsin for sepsis diagnosisHealth Condition 1: A419- Sepsis, unspecified organism
CTRI/2018/10/016077All India Institute of Medical Sciences Jodhpur
Active, not recruiting
Not Applicable
The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas PatientsSoft-tissue SarcomaPredictive Cancer Model
NCT05741944Leiden University Medical Center120